Research Topics
Genomes and Genes
| Anas YounesSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialAnas Younes
Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Lancet Oncol 12:1222-8. 2011..We tested the safety and efficacy of mocetinostat, an oral isotype-selective histone deacetylase inhibitor, in patients with relapsed classical Hodgkin's lymphoma...- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma SubtypesAnas Younes
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
J Clin Oncol 30:4161-7. 2012..CONCLUSION SB1518 has encouraging activity in relapsed lymphoma, providing the first proof-of-principle of the potential therapeutic value of targeting the JAK/STAT pathway in lymphoma in the clinical setting... - Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphomaAnas Younes
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 30:2776-82. 2012..We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a first-in-man phase I clinical trial in patients with relapsed lymphoma... - Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II studyAnas Younes
MD Anderson Cancer Center, 1515 Holcombe Blvd, Unite 429, Houston, TX 77030, USA
J Clin Oncol 30:2197-203. 2012..Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population... - Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 30:2183-9. 2012..In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas... 
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes
Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 119:4123-8. 2012..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...- Histone deacetylase inhibitors in Hodgkin lymphomaDaniela Buglio
Department of Lymphoma Myeloma, 1515 Holcombe Boulevard, Box 429, Houston, TX 77030, USA
Invest New Drugs 28:S21-7. 2010..This review will focus on the emerging role of histone deacetylase inhibitors in patients with relapsed HL... 
Nuclear transcription factor-kappaB in Hodgkin's diseaseAnas Younes
Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429 Houston, TX 77030, USA
Leuk Lymphoma 44:929-35. 2003..Numerous studies have shown that Hodgkin's disease cells exhibit constitutive active NF-kappaB. The present review examines the mechanism how NF-kappaB is activated and its relevance to Hodgkin's disease...- Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphomaAnas Younes
M. D. Anderson Cancer Center, University of Texas, Houston, TX 77030-4009, USA
Clin Lymphoma 3:257-9. 2003 - A pilot study of rituximab in patients with recurrent, classic Hodgkin diseaseAnas Younes
Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:310-4. 2003..Rituximab is used to primarily deplete normal B cells from HD lesions... - Angiogenesis in lymphoma: a short reviewAnas Younes
Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
Curr Mol Med 5:609-13. 2005..This short review focuses on recent advances in angiogenesis-research in non-Hodgkin's lymphoma and Hodgkin's disease... - Clinicopathologic and molecular features of Hodgkin's lymphomaAnas Younes
Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Biol Ther 2:500-7. 2003..Novel treatment strategies based on our understanding of Hodgkin's lymphoma biology are currently being explored to maintain the high cure rate without the added treatment related toxicity... - A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphomaAnas Younes
Section of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX, USA
Clin Lymphoma 4:183-5. 2003 - Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's diseaseAnas Younes
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:5432-8. 2004..The purpose of this study was to evaluate the clinical activity and toxicity of recombinant human Interleukin (IL)-12 in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)... - Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphomaAnas Younes
Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Eur J Cancer 42:2976-81. 2006..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule... - Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answersAnas Younes
Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, Texas 77030, USA
Autophagy 4:707-9. 2008..Here, we discuss the potential molecular mechanisms underlying this activity, and how to improve the therapeutic value of mTOR inhibitors by combining them with other agents that may target different molecular pathways... - CD30-targeted antibody therapyAnas Younes
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Oncol 23:587-93. 2011..This article reviews the current knowledge of therapeutic targeting of CD30+ cancers using naked and conjugated monoclonal antibodies... - Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphomaA Younes
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Leuk Lymphoma 40:79-85. 2000..We conclude that 9-cis RA has a modest activity in relapsed and refractory NHL. In this study, responses were observed in patients with B-cell lymphomas and those with T-cell lymphomas... - Utility of mTOR inhibition in hematologic malignanciesAnas Younes
Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncologist 16:730-41. 2011..Thus far, promising results have been seen with the application of mTOR inhibitors as single agents in patients with relapsed or refractory leukemia, HL, NHL, MM, and WM... - Beyond chemotherapy: new agents for targeted treatment of lymphomaAnas Younes
Department of Lymphoma and Myeloma, Unit 429, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Nat Rev Clin Oncol 8:85-96. 2011..This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward... - Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasAnas Younes
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 363:1812-21. 2010.... - A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Br J Cancer 103:1783-7. 2010.... - Predicting treatment outcome in classical Hodgkin lymphoma: genomic advancesEnrico Derenzini
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, Texas, USA
Genome Med 3:26. 2011..In this review, we focus on the prognostic tools and biomarkers that are available for newly diagnosed HL, and we highlight recent advances in the genomic characterization of classical HL and potential targets for therapy... - A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphomaChul S Ha
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 63:188-93. 2005..MR was defined as disappearance of t(14;18) (q32;q21) amplified by polymerase chain reaction (PCR)... - Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 150:200-8. 2010..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL... - High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera
Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 23:7013-23. 2005..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)... - The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell linesManuela Lemoine
Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 119:4017-25. 2012.... - Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaYasuhiro Oki
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 112:831-6. 2008..The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL... - The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expressionGeorgios V Georgakis
Departments of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
Exp Hematol 34:1670-9. 2006..CONCLUSION: Our data demonstrate that targeting HSP90 function by 17-AAG may offer a novel therapeutic strategy for ALCL, either as single-agent activity or by combining 17-AAG with conventional or targeted therapeutic schemes... - Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell deathGeorgios V Georgakis
Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center (MDACC, Houston, TX 77030, USA
Br J Haematol 130:501-10. 2005..Our data demonstrate that HGS-ETR1 and HGS-ETR2 monoclonal antibodies can induce cell death in a variety of cultured and primary lymphoma cells, and may have therapeutic value in lymphoma... - Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell deathGeorgios V Georgakis
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 12:584-90. 2006.... - Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:481-5. 2006..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time... - Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptorsBei Zheng
Departments of Lymphoma/Myeloma, Bioimmunotherapy, and Cancer Biology, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:3207-15. 2004..CONCLUSIONS: The in vitro activity of PS-341 against HD-derived cell lines suggests that PS-341 may have a therapeutic value for the treatment of HD... - Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
J Clin Oncol 23:667-75. 2005..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma... - Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou
Department of Lymphoma and Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
Blood 100:4351-7. 2002..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND... - Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:345-53. 2005..The overall safety profile for FND was good. However, patients should be monitored for opportunistic infections, and prophylactic antibiotics are recommended, particularly against PCP... - The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitorsAdam Jona
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, USA
Exp Hematol 39:1007-1017.e1. 2011..Based on promising in vitro and in vivo activity of several histone deacetylase inhibitors in Hodgkin lymphoma (HL), we investigated SNDX-275, an oral class 1 isoform-selective histone deacetylase inhibitors in HL-derived cell lines... - The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanismDaniela Buglio
M D Anderson Cancer Center, Department of Lymphoma Myeloma, Houston, University of Texas, TX, USA
Br J Haematol 151:387-96. 2010..Thus, our results demonstrate that MGCD0103 may synergize with proteasome inhibitors by HDAC6-independent mechanisms, providing mechanistic rationale for exploring this potentially less toxic combination for the treatment of lymphoma... - Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang
The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
J Clin Oncol 22:4095-102. 2004..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL... - Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphomaVictor Y Yazbeck
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
Exp Hematol 36:443-50. 2008..To investigate the mechanisms of antiproliferative effect induced by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in mantle cell lymphoma (MCL)... - Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 27:5213-8. 2009..This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL)... - Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:1818-21. 2006..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL... - Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphomaAmanda Wedgwood
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Lymphoma Myeloma 8:S63-6. 2007..However, randomized studies are needed to clarify the role of primary prophylaxis with ABVD and BEACOPP-baseline regimens. Secondary prophylaxis should be considered in all patients, especially those who develop neutropenic fever... - Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphomaElias Jabbour
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:2481-9. 2007.... - The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9Georgios V Georgakis
Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center (MDACC, Houston, TX, USA
Br J Haematol 135:68-71. 2006..These data suggest that 17-AAG may have a potential therapeutic value in patients with MCL... - Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphomaGeorgios V Georgakis
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Br J Haematol 132:503-11. 2006..Our data suggest that PTEN phosphorylation and activation of CD30, CD40 and RANK may play a role in activating Akt in HRS cells... - Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortalityHarrys A Torres
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA
Clin Lymphoma Myeloma 6:393-8. 2006..01). CONCLUSION: In an era of intense and pleiotropic immunosuppressive therapy in patients with lymphoma, CMV-A and CMV-D are significant infections. Preventive strategies might be warranted for patients at risk... - Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri
Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 23:2240-7. 2005.... - Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphomaBarbara Pro
Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Br J Haematol 143:355-60. 2008..In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial... - Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 55:36-43. 2003.... - Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Lancet Oncol 13:716-23. 2012.... - Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphomaIssa F Khouri
Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 21:4407-12. 2003..Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma... - Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphomaYasuhiro Oki
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:77-83. 2007.... - HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphomaDaniela Buglio
Departments of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Blood 117:2910-7. 2011..These results demonstrate for the first time that HDAC11 plays an essential role in regulating OX40L expression. Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL... - Does rituximab have a place in treating classic hodgkin lymphoma?Yasuhiro Oki
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA
Curr Hematol Malig Rep 5:135-9. 2010..These trials further clarify the role of rituximab in cHL. Enrollment of patients with this "classic" disease in clinical trials is encouraged... - New molecular targets for treatment of lymphomaBarbara Pro
Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA
Curr Oncol Rep 6:360-8. 2004..In this review, we focus on new molecular targets that are being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease... - Thalidomide for patients with recurrent lymphomaBarbara Pro
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:1186-9. 2004..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease... - Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene productsKwang Seok Ahn
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:2286-95. 2007..Thus, overall, our results indicate that salinosporamide A enhances apoptosis, suppresses osteoclastogenesis, and inhibits invasion through suppression of the NF-kappaB pathway... - Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell linesDaniela Buglio
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 112:1424-33. 2008.... - Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disordersAnas Younes
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:458-67. 2003..The potential therapeutic use of these members also is discussed... - Expression of heat-shock protein-90 in non-Hodgkin's lymphomasJose R Valbuena
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mod Pathol 18:1343-9. 2005..These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients... - Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer CenterQi Liu
Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:1582-9. 2006..The apparent plateau in the FFS curve, starting approximately 8 to 10 years from the beginning of treatment, raises the issue of the potential curability of these patients... - MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survivalBei Zheng
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX 77030, USA
Blood 102:1019-27. 2003..These findings provide a proof-of-principle that inhibition of the MEK/ERK pathway may have therapeutic value in HD... - Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomasNina Shah
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Leuk Lymphoma 53:50-6. 2012..Though the FLIPI model remains the gold standard for prognosis, these quantitative serologic markers may be useful as adjunct tools in assessing disease risk... - Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyondGeorgios V Georgakis
The University of Texas, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Future Oncol 1:273-81. 2005..This paper will review the recent advances in HSP90-biology and will discuss the emerging role of the HSP90 inhibitors such as 17-allylamino-17 demethoxy-geldanamycin and other HSP-90-directed small molecules in cancer therapy... - Hodgkin lymphoma risk: role of genetic polymorphisms and gene-gene interactions in DNA repair pathwaysClaudia M Monroy
Department of Epidemiology, M D Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
Mol Carcinog 50:825-34. 2011..These findings suggest that DNA repair variants in BER and DSB pathways may play an important role in the development of HL... - Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang
MD Anderson Cancer Center, Houston, TX 77030, USA
Oncol Rep 10:1513-8. 2003..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications... - K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosisSuizhao Wang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 109:2174-82. 2007..K1 may contribute to lymphoma development by stimulating cell survival by selectively blocking Fas-mediated apoptosis... - Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737Kensuke Kojima
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 118:1023-31. 2012..The role of p53 in sensitivity of CLL cells to BCL-2 inhibition has not been extensively investigated... - Novel small-molecule therapy of Hodgkin lymphomaDaniela Buglio
Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
Expert Rev Anticancer Ther 7:735-40. 2007..In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity... - Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapyAnas Younes
Department of Lymphoma and Myeloma, Unit 429, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 21:3526-34. 2003.... - Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphomaYasuhiro Oki
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Cancer 104:781-7. 2005..The favorable safety profile and the ease of its administration in outpatient settings warrant investigating it in combination with other active drugs for the treatment of recurrent and refractory NHL... - Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 97:586-91. 2003..The impact of endoscopic assessment on the management of MCL patients is unknown... - Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityI F Khouri
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Blood 98:3595-9. 2001..Further studies are warranted to compare nonablative allogeneic hematopoietic transplantation with alternative treatment strategies... - Monoclonal antibodies in the treatment of non-Hodgkin's lymphomaMichelle A Fanale
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Drugs 67:333-50. 2007.... - Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosisGeorge Z Rassidakis
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mod Pathol 17:946-53. 2004.... - Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemiasMarina Konopleva
Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 3:1249-62. 2004.... - New treatment strategies for aggressive lymphomaAnas Younes
Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 31:10-3. 2004..Consequently, the CHOP-14 regimen (in which the dose intensity is 50% greater than that of the standard regimen) has been adopted by many oncologists for the treatment of aggressive NHL... - Histone deacetylase inhibitors in the treatment of lymphomaManuela Lemoine
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Discov Med 10:462-70. 2010..This review focuses on the use of HDAC inhibitors in the treatment of relapsed lymphoma... - Impact of high-dose chemotherapy on peripheral T-cell lymphomasJ Rodriguez
Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 19:3766-70. 2001..Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation... - Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini
The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
Haematologica 93:257-64. 2008..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen... - Hodgkin's lymphoma: molecular targets and novel treatment strategiesVictor Yazbeck
MD Anderson Cancer Center, Department of Lymphoma Myeloma, Houston, Texas, USA
Future Oncol 2:533-51. 2006..Future treatment strategies will also be discussed based on our understanding of HL biology... - From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapyGeorgios V Georgakis
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Expert Rev Anticancer Ther 6:131-40. 2006..This article provides a brief analysis of the PI3K/Akt/mTOR pathway, its importance in tumor pathogenesis and the current status of preclinical and clinical studies targeting signaling components of this pathway... - Cytomegalovirus pneumonia in patients with lymphomaRoy F Chemaly
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, 77230, USA
Cancer 104:1213-20. 2005..Even when treated with antiviral therapy, cytomegalovirus pneumonia (CMVp) is associated with high morbidity and mortality in immunocompromised patients. CMVp has been rarely reported in patients with lymphoma... - European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin diseaseRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:1731-8. 2002.... - Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Ann Oncol 12:923-7. 2001..We conducted a phase II clinical trial to investigate the activity and tolerability of the combination of both drugs... - Irinotecan in relapsed or refractory non-Hodgkin's lymphomaA H Sarris
Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Oncology (Williston Park) 15:53-6. 2001..Accrual to this study is continuing for better determination of the response rate in all histologic subtypes of non-Hodgkin's lymphoma... - Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphomaI F Khouri
Department of Hematology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
J Clin Oncol 16:3803-9. 1998..After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation... - Infusional vinorelbine in relapsed or refractory lymphomasA H Sarris
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Leuk Lymphoma 39:291-9. 2000..The role of vinorelbine in combination regimens for patients with relapsed lymphomas, particularly those of indolent histology, should be further investigated... - Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimenP Anderlini
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Bone Marrow Transplant 35:943-51. 2005..03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival... - The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphomaM J Overman
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Ann Oncol 19:553-9. 2008..The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied... - Targeting lymphoma cells and their microenvironment with novel antibodiesAmanda Wedgwood
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma Myeloma 7:S33-40. 2006..Continued investigation is encouraged to combine monoclonal antibodies with other targeted therapies and incorporate their use into standards of care in the treatment of lymphoma... - Rituximab: review and clinical applications focusing on non-Hodgkin's lymphomaK M King
Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Expert Rev Anticancer Ther 1:177-86. 2001..Furthermore, it is currently being evaluated in several nonmalignant diseases, such as autoimmune disorders. This review will focus on the role of rituximab in patients with non-Hodgkin's lymphoma... - The lymphomas: molecular pathways and novel therapeutic targetsAmanda Wedgwood
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Curr Hematol Rep 4:324-34. 2005..In this review, we focus on new molecular targets that are currently being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's lymphoma... - Heat shock protein-based cancer vaccinesYasuhiro Oki
Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Expert Rev Vaccines 3:403-11. 2004..HSP-based vaccines are a novel vaccine preparation with a promising role in cancer management. Further studies to determine the administering strategy and specific indication are warranted... - Novel treatment strategies for aggressive non-Hodgkin's lymphomaLuis Fayad
Department of Lymphoma/Myeloma, University of Texas, MD Anderson Cancer Center, Box # 429, Houston, TX 77030, USA
Expert Opin Pharmacother 7:733-48. 2006..New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate... - Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survivalK van Besien
Division of Medicine, Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, USA
Bone Marrow Transplant 27:397-404. 2001..Long-term survival in recurrent large cell lymphoma is influenced more by disease characteristics than by the type of salvage regimen used... - CD30 ligand in lymphoma patients with CD30+ tumorsA Younes
Department of Hematology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
J Clin Oncol 15:3355-62. 1997..The role of sCD30 in protecting tumor cells from CD30L-mediated cell death and the pattern of CD30L expression on human peripheral-blood lymphocytes (PBLs) of normal donors and patients with CD30+ tumors are investigated... - Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell linesP Fiumara
Department of Lymphoma and Myeloma, Head and Neck Surgery, and Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 98:2784-90. 2001..The coexpression of RANK and RANKL in H/RS cells suggests that they may regulate cytokine and chemokine secretion in H/RS cells by an autocrine mechanism... - Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlationsR Munker
University of Texas, M D Anderson Cancer Center, Department of Hematology, Houston, USA
Leuk Lymphoma 27:517-21. 1997..We conclude that within the confines of this study, SCD95 has no prognostic value in patients with NHL... - Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trialG Steinbach
Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas, M D Anderson Cancer Center, and Houston Veterans Affairs Medical Center, 77030, USA
Ann Intern Med 131:88-95. 1999..Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth...
Research Grants
- Clinical Activity of 17-AAG in LymphomaAnas Younes; Fiscal Year: 2007..In Aim 3 we will correlate the biologic effects of 17-AAG and clinical response in patients with relapsed MCL, ALCL, and HL. ..